EyePoint's Phase 3 failure; Lilly's China drug delivery deal

Plus news about Longwood's next fund and Ryzumvi's label expansion. EyePoint drug fails, biotech halves staff: The Watertown, MA-based biotech is letting go of 53% of its positions after its experimental ...